Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Natelli

Geriatric Medicine Paterson, NJ Medical Doctor

NPI 1740237940 CMS profile 78662

703 Main St, Paterson, NJ 07503

Open in the dashboard

General payments

$734

49 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Natelli of Paterson, NJ is reported in the CMS Open Payments database as having received $734 across 49 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $124 7
2024 General $140 8
2023 General $41 3
2022 General $36 2
2021 General $159 12
2020 General $111 8
2019 General $122 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Natelli
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Anthony Natelli were reported at $124. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Anthony Natelli Geriatric Medicine median Middle half National median
2019 $122 $122 $40–$435 $163
2020 $111 $98 $25–$349 $114
2021 $159 $125 $34–$441 $132
2022 $36 $124 $36–$408 $149
2023 $41 $121 $41–$383 $160
2024 $140 $134 $41–$435 $164
2025 $124 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $129 9 payments
  2. Pfizer Inc. $108 7 payments
  3. Merck Sharp & Dohme Corporation $95 7 payments
  4. Ge Healthcare $87 6 payments
  5. Lilly USA, LLC $63 4 payments
  6. Amgen Inc. $43 3 payments
  7. Exact Sciences Corporation $42 2 payments
  8. Horizon Therapeutics plc $38 3 payments
  9. Medtronic, Inc. $22 1 payment
  10. Novartis Pharmaceuticals Corporation $21 1 payment
  11. Other $86 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $734 49 payments
Products named General payments · program years 2019–2025
  1. JANUVIA $95 7 payments
  2. FARXIGA $72 5 payments
  3. STEGLATRO $54 4 payments
  4. STEGLUJAN $53 4 payments
  5. AIMOVIG $43 3 payments
  6. Repatha $43 3 payments
  7. Cologuard Collection Kit $42 2 payments
  8. ELIQUIS $42 3 payments
  9. JANUMET $41 3 payments
  10. COLOGUARD DNA CAPTURE REAGENTS $41 3 payments
  11. Other $434 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,737

Median for Internal Medicine: 777

Drug cost

$128,004

Median for Internal Medicine: $73,373

Branded share of claims

17.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 51 $56,987
Januvia Sitagliptin Phosphate Brand 20 $27,844
Farxiga Dapagliflozin Propanediol Brand 11 $9,478
Breo Ellipta Fluticasone/Vilanterol Brand 13 $7,536
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 11 $6,001
Atorvastatin Calcium Generic 186 $2,088
Rosuvastatin Calcium Generic 121 $1,783
Losartan Potassium Generic 100 $1,147
Ezetimibe-Simvastatin Ezetimibe/Simvastatin Brand 30 $1,139
Metoprolol Succinate Generic 85 $1,100

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

49 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record